Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

LQDA
Liquidia Corporation Common Stock
stock NASDAQ

At Close
Sep 30, 2026 3:59:57 PM EDT
30.20USD-57.278%(-40.49)22,769,402
30.11Bid   30.25Ask   0.14Spread
Pre-market
Sep 30, 2026 8:38:30 AM EDT
71.00USD+0.439%(+0.31)4,473
After-hours
Sep 30, 2026 4:59:30 PM EDT
30.40USD+0.662%(+0.20)180,241
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
06:22AM EST  Needham Maintains Buy on Liquidia, Raises Price Target to $12   Benzinga
Jan 7, 2022
01:04PM EST  Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40M   Benzinga
09:03AM EST  Liquidia Re-Finances Debt Facility With Silicon Valley Bank To   GlobeNewswire Inc
Jan 4, 2022
08:11AM EST  The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives   Benzinga
Jan 3, 2022
04:53PM EST  Liquidia Names Roger Jeffs CEO   Benzinga
04:52PM EST  Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds Damian deGoa who will remain a director of the Company and will provide transition support through January 31, 2022.   GlobeNewswire Inc
Dec 29, 2021
06:46AM EST  Stipulation Of Partial Judgment In Favor Of Liquidia Filed In Hatch-Waxman Litigation   Benzinga
06:45AM EST  Stipulation of Partial Judgment In Favor of Liquidia Filed In   GlobeNewswire Inc
Nov 11, 2021
04:42PM EST  Liquidia to Participate In Jefferies London Healthcare Conference Nov. 18   Benzinga
04:30PM EST  Liquidia to Participate in the Jefferies London Healthcare Conference   GlobeNewswire Inc
Nov 9, 2021
10:49AM EST  UPDATE: Needham On Liquidia Price Target Raise: Positive On 'Tentative FDA Approval For The Treatment Of Pulmonary Arterial Hypertension' Given Yutrepia Meets All FDA Standards For Approval; Sees Co. 'In A Much Stronger Position' Ahead Of March 2022 Trial   Benzinga
10:48AM EST  Watching Liquidia; Needham Raises Price Target To $8   Benzinga
10:48AM EST  Watching Liquidia; Hearing Needham Raises Price Target To $8   Benzinga
Nov 8, 2021
10:12AM EST  Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH   Benzinga
05:45AM EST  -- First dry-powder formulation of treprostinil to meet criteria required for FDA approval -- Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation -- Conference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time   GlobeNewswire Inc
Nov 3, 2021
06:57PM EDT  Liquidia Technologies Q3 EPS $(0.14) Up From $(0.40) YoY   Benzinga
Oct 11, 2021
09:36AM EDT  Liquidia Late Friday Announced US Patent Trial And Appeal Board Ruled In Favor In Inter Partes Review Proceeding Against United Therapeutics' '901 Patent   Benzinga
06:08AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.55 A.M. EDT).   RTTNews
Oct 8, 2021
05:23PM EDT  Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 9,604,901 (901 patent) owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso (treprostinil inhalation solution).   GlobeNewswire Inc
Sep 22, 2021
04:12PM EDT  Liquidia Files For 8.6M Share Offering Via Selling Stockholders, No Price Disclosed   Benzinga
Sep 10, 2021
08:29AM EDT  Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which runs from September 13 15, 2021. The conference will be held in a virtual format.   GlobeNewswire Inc
Aug 18, 2021
04:34PM EDT  FDA Completes On-site Pre-Approval Inspection Of Liquidia's Morrisville, North Carolina Facility   Benzinga
04:15PM EDT  FDA Completes On-site Pre-Approval Inspection of   GlobeNewswire Inc
Aug 12, 2021
08:03AM EDT  US Patent Trial And Trademark Appeal Board Decides To Institute Inter Partes Review Of United Therapeutics' Tyvaso Patent   Benzinga
08:00AM EDT  Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 (793 patent), owned by United Therapeutics Corporation (UTC) and listed in the Orange Book for Tyvaso (treprostinil).   GlobeNewswire Inc
Aug 10, 2021
07:24AM EDT  Liquidia Technologies Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $3.38M Beat $1.72M Estimate   Benzinga
07:09AM EDT  Liquidia: Q2 Earnings Insights   Benzinga
07:00AM EDT  -- Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunity -- Resubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powder -- Improved balance sheet with private placement and increased financial discipline -- Company to host webcast and conference call today at8:30 a.m. ET   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:00AM EDT  Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss financial results and provide a corporate update.   GlobeNewswire Inc
Jun 7, 2021
06:02AM EDT  United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia   RTTNews
06:02AM EDT  United Therapeutics Pursues Additional Claims For Trade Secret Misappropriation Against Liquidia And A Former United Employee; Claims Allege Liquidia 'conspired with the former employee to misappropriate United Therapeutics' trade secrets'   Benzinga
06:01AM EDT  United Therapeutics Pursues New Claims For Trade Secret Misappropriation   PR Newswire
Jun 2, 2021
07:19AM EDT  Liquidia Says FDA Accepted NDA Resubmission For LIQ861 Inhalation Powder To Treat PAH   RTTNews
07:02AM EDT  Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 Inhalation Powder   Benzinga
07:00AM EDT  Liquidia Announces FDA Acceptance of New Drug Application   GlobeNewswire Inc
May 26, 2021
07:00AM EDT  Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference.   GlobeNewswire Inc
May 25, 2021
07:53AM EDT  The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal   Benzinga
May 24, 2021
04:07PM EDT  Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration   Benzinga
04:05PM EDT  Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that Sandoz Treprostinil Injection, a generic form of Remodulin, is now also available for subcutaneous (SC) administration to treat patients diagnosed with pulmonary arterial hypertension (PAH).   GlobeNewswire Inc
May 19, 2021
04:35PM EDT  Liquidia Form 4 Filing From Co. General Counsel, Russell Schundler, Shows Purchase Of 97.755K Shares Of Co. Stock   Benzinga
May 13, 2021
07:03AM EDT  Liquidia Technologies Q1 EPS $(0.21), Inline, Sales $3.08M Beat $870.00K Estimate   Benzinga
07:00AM EDT  - Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery- Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder- Improved financial position with private placement and access to new credit facility- Company to host webcast and conference call today at8:30 a.m. ET   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 10, 2021
06:41AM EDT  Liquidia Resubmits NDA For LIQ861 Inhalation Powder For Treatment Of Pulmonary Arterial Hypertension   RTTNews
06:31AM EDT  Liquidia Resubmits New Drug Application for LIQ861 Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension   Benzinga
06:30AM EDT  Liquidia Resubmits New Drug Application for LIQ861 (treprostinil)   GlobeNewswire Inc
May 6, 2021
07:00AM EDT  Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2021 financial results on Thursday, May 13, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss financial results and provide a corporate update.   GlobeNewswire Inc
Apr 18, 2021
08:52AM EDT  Last Week's Notable Insider Buys Included Evergy, StoneMor, Tattooed Chef And More   Benzinga
Apr 15, 2021
10:20AM EDT  Mid-Morning Market Update: Markets Open Higher; Bank of America Beats Q1 Estimates   Benzinga
10:06AM EDT  Liquidia Director Paul Manning Purchases 198,413 Shares At Avg Price Of $2.52 In Open Market   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
07:17AM EDT  Liquidia Enters Common Stock Purchase Deal For Private Placement Of 8.63 Mln Shares At $2.52/Shr   RTTNews
07:06AM EDT  Liquidia Corporation Announces $21.7M Private Placement; 8,626,037 Shares At $2.52/Share   Benzinga
07:00AM EDT  Liquidia Corporation Announces $21.7 Million Private Placement   GlobeNewswire Inc
Apr 7, 2021
07:00AM EDT  Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the 20th Annual Needham Virtual Healthcare Conference.   GlobeNewswire Inc
Mar 30, 2021
07:09AM EDT  Liquidia Announces Generic Treprostinil Injection Will Be Available For Subcutaneous Route Of Administration   Benzinga
07:00AM EDT  -- Addressable market for generic Treprostinil Injection more than doubles -- FDA cleared 510(k) for RG 3ml Medication Cartridge for use with CADD-MS 3 pump   GlobeNewswire Inc
Mar 23, 2021
01:19PM EDT  Needham Maintains Buy on Liquidia, Lowers Price Target to $5   Benzinga
11:23AM EDT  Liquidia shares were trading higher after the company reported FY20 EPS results up from last year.   Benzinga
07:11AM EDT  Liquidia Reports FY20 EPS $(1.76) Up From $(2.57) YoY   Benzinga
07:00AM EDT  - Integrated RareGen (now known as Liquidia PAH) to establish commercial presence in PAH- Clarified path towards submitting response to CRL for LIQ861 in mid-2021- Reducing net annual spending more than 40% in 2021 compared to 2020 cash burn- Company to host webcast and conference call today at8:30 a.m. ET   GlobeNewswire Inc
04:26AM EDT  Earnings Scheduled For March 23, 2021   Benzinga
Mar 9, 2021
07:30AM EST  Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The company will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and provide a corporate update.   GlobeNewswire Inc
Mar 2, 2021
08:30AM EST  Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021, with Silicon Valley Bank, which provides Liquidia with up to $20.5 million in term loans of which the first $10.5 million was funded at closing.   GlobeNewswire Inc
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 20, 2020
12:05AM EST  Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (Liquidia or the Company) (NASDAQ: LQDA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Dec 16, 2020
05:21PM EST  Liquidia Corp Earlier Filed For Mixed Shelf Of Up To $200M   Benzinga
Dec 14, 2020
09:29AM EST  Liquidia Corporation Announces CEO Transition   Benzinga
09:28AM EST  Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the Company, effective immediately. He succeeds Neal F. Fowler who has retired as CEO and a director of the Company. Mr. Fowler has agreed to provide assistance to the Company for a short period of time to support a smooth transition.   GlobeNewswire Inc
Dec 12, 2020
08:13PM EST  Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (Liquidia or the Company) (NASDAQ: LQDA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Dec 4, 2020
06:19AM EST  HC Wainwright & Co. Initiates Coverage On Liquidia with Buy Rating, Announces Price Target of $6   Benzinga
Nov 30, 2020
08:55PM EST  Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (Liquidia or the Company) (NASDAQ: LQDA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
07:15AM EST  Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidias interim CFO since August 2020. Mr. Bariahtaris has agreed to provide assistance to the Company for a short period of time to support a smooth transition.   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 28, 2020
01:08PM EST  Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates   Benzinga
Nov 25, 2020
11:10PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
07:19AM EST  Liquidia: FDA Issues CRL For LIQ861; CRL Focuses On Drug   RTTNews
07:07AM EST  Liquidia Technologies: FDA Issues Complete Response Letter For NDA For LIQ861 Inhalation Powder   RTTNews
07:07AM EST  CORRECTION: Liquidia Ticker Is LQDA   Benzinga
07:06AM EST  Liquidia Says CRL Identified 'need for additional information and clarification on chemistry, manufacturing and controls (CMC) data'; Co. 'does not believe that the items raised in the CRL will be a barrier to the ultimate approval of LIQ861'   Benzinga
07:03AM EST  Liquidia Receives Complete Response Letter From FDA For LIQ861 Inhalation Powder For Treatment Of Pulmonary Arterial Hypertension; Says 'In the CRL, the FDA stated that it is unable to approve the NDA at this time'   Benzinga
07:00AM EST  Liquidia Receives Complete Response Letter from FDA for LIQ861   GlobeNewswire Inc
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 20, 2020
10:28AM EST  Wedbush Downgrades Liquidia Technologies to Neutral, Lowers Price Target to $4   Benzinga
Nov 18, 2020
04:01PM EST  MergerReinforces Companys Commitment to Patients with PAH   GlobeNewswire Inc
Nov 16, 2020
07:15AM EST  Liquidia Announces Results of Special Meeting of Stockholders   GlobeNewswire Inc
Nov 12, 2020
10:06AM EST  Liquidia to Present at the 2020 Jefferies Virtual London   GlobeNewswire Inc
Nov 9, 2020
07:40AM EST  Liquidia Technologies Q3 EPS $(0.40) Misses $(0.36) Estimate   Benzinga
07:15AM EST  - Raised $75 Million through Underwritten Public Offering- Bolsteredand Defended LIQ861 Patent Position- Advanced Efforts in Support of the RareGen, LLC Merger and Integration- Company to Host Webcast and Conference Call Today at8:00a.m. ET   GlobeNewswire Inc
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
03:33AM EST  Earnings Scheduled For November 6, 2020   Benzinga
Nov 2, 2020
02:33PM EST  Mid-Afternoon Market Update: Nasdaq Turns Lower; Endurance International Shares Spike Higher   Benzinga
12:26PM EST  Mid-Day Market Update: Superior Industries Jumps Following Q3 Results; Jounce Therapeutics Shares Plummet   Benzinga
10:18AM EST  Mid-Morning Market Update: Markets Open Higher; Este Lauder Profit Tops Views   Benzinga
07:23AM EST  Liquidia Reschedules Special Meeting Of Stockholders And Reaffirms Recommendation To Approve Proposed Acquisition Of RareGen, LLC; Says Determined Recent Unsolicited Offer 'does not Constitute Superior Proposal'   Benzinga
07:15AM EST  Company Determines Unsolicited Offer does not Constitute Superior Proposal   GlobeNewswire Inc
Oct 30, 2020
08:40PM EDT  UPDATE Liquidia to Report Third Quarter 2020   GlobeNewswire Inc
04:15PM EDT  Liquidia to Report Third Quarter 2020 Financial Results and   GlobeNewswire Inc
Oct 19, 2020
02:50PM EDT  Why Liquidia's Stock Is Trading Higher Today   Benzinga
08:35AM EDT  Liquidia Announces Postponement Of Special Meeting Of Stockholders, Originally Scheduled Oct. 21   Benzinga
08:30AM EDT  Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINTtechnology, today announced that it has postponed the special meeting of stockholders, originally scheduled for October 21, 2020.   GlobeNewswire Inc
Oct 14, 2020
09:27AM EDT  Liquidia Technologies Announces That U.S. Patent Trial And Appeal Board Has Ruled Against United Therapeutics On Tyvaso Patents   Benzinga
09:25AM EDT  Liquidia Provides Update on U.S. Patent Trial and Appeal Board   GlobeNewswire Inc
Oct 5, 2020
07:15AM EDT  Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINTtechnology, today announced the appointment of Dr. Gerald M. OBrien as Vice President, Pulmonary Clinical Development, effective immediately.   GlobeNewswire Inc
Sep 17, 2020
07:19AM EDT  Liquidia Announces A Special Meeting Date On October 21, 2020, at 4:30 P.M. Eastern Time For Stockholders To Vote On The Proposed Acquisition Of RareGen   Benzinga
07:15AM EDT  Liquidia Announces Special Meeting Date to Approve Proposed   GlobeNewswire Inc
Aug 28, 2020
07:16AM EDT  Liquidia Announces Notice Of Allowance For US Patent Application Covering Methods Of Treating Pulmonary Hypertension With Dry Powder Treprostinil   Benzinga
Aug 20, 2020
09:18AM EDT  Liquidia Announces Chief Financial Officer Transition   Benzinga
Aug 10, 2020
07:26AM EDT  Liquidia Technologies Q2 EPS $(0.49) Misses $(0.44) Estimate   Benzinga
07:15AM EDT  Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 INSPIRE TrialAppointed Tushar Shah, M.D. as Chief Medical OfficerAnnounced Definitive Agreement to Acquire RareGen, LLCCompleted Public Offering of Common StockCompany to Host Webcast and Conference Call Today at4:30 p.m. ET   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 5, 2020
08:32AM EDT  Liquidia Releases Exploratory Endpoint Data From INSPIRE Study At The American Throacic Society (ATS) Annual Meeting   Benzinga
07:15AM EDT  Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at   GlobeNewswire Inc
Aug 3, 2020
09:20AM EDT  Liquidia to Report Second Quarter 2020 Financial   GlobeNewswire Inc
Jul 24, 2020
09:12AM EDT  Liquidia Technologies Issues Response To United Therapeutics Suit Alleging Infringement Of Tyvaso Patent: Notes Statutory 30-Month Stay On Regulatory Approval Is Not Associated With Allegations Of '793 Patent, Should Have No Effect On FDA Review   Benzinga
09:09AM EDT  Liquidia Responds to United Therapeutics Corporation Lawsuit   GlobeNewswire Inc
Jul 23, 2020
06:04AM EDT  United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia; Filed an Amended Complaint Against Liquidia   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC